Press releases
- PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- 4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
- PAVmed Provides Business Update and First Quarter 2024 Financial Results
- Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
- Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
- Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
- PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
- Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
- PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
More ▼
Key statistics
On Thursday, PAVmed Inc (1P50:BER) closed at 0.00, -100.00% above its 52-week low of 2.44, set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 9.43m |
Free float | 8.84m |
P/E (TTM) | -- |
Market cap | 10.00m USD |
EPS (TTM) | -9.08 USD |
Data delayed at least 15 minutes, as of Dec 07 2023 07:32 GMT.
More ▼